OIS at AAO 2015

Translatum Medicus, Inc.

Nov 12, 2015 11:33am ‐ Nov 12, 2015 11:41am


TMi de-risks and accelerates drug development for dry Age Related Macular Degeneration.
TMi’s patented lead compound, TMi-018, is a first-in-class modulator of the innate immune system, with demonstrated safety in clinical trial for non-ophthalmic indications. In TMi’s pre-clinical model, it reduces geographic atrophy, uniquely aligning with clinical trial design.


  • Shelley Boyd, MD, President & CSO, Translatum Medicus, Inc.

You must be logged in and own this session in order to post comments.